On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Fuji Stresses No Supply Impact, Denies Patent Allegations over Eylea Biosimilar
November 17, 2025
-
REGULATORY Elrexfio to Escape CEA-Based Price Tweak, Analysis to Resume for Paxlovid
November 17, 2025
-
BUSINESS Novartis Overhauls Sales Model to Prioritize Solving Regional Treatment Gaps
November 14, 2025
-
REGULATORY Nipro-Samsung Alliance Nears First Approval in Japan with Stelara Biosimilar
November 14, 2025
-
REGULATORY Japan Panel to Review KalVista’s Oral HAE Drug, GSK’s Asthma Med, and More on Nov. 27
November 14, 2025
-
BUSINESS Keytruda Again Tops Japan Market in July-September: IQVIA
November 14, 2025
-
BUSINESS Bayer, Regeneron Move to Block Fuji’s Newly Listed Eylea Biosimilar in Japan
November 13, 2025
-
REGULATORY LDP Study Group Seeks Uniform 5% Drug Price Hike, Warns of US MFN Spillover
November 12, 2025
-
BUSINESS J&J Japan Targets Top Share in Key Disease Areas by 2030: New President
November 12, 2025
-
REGULATORY Japan’s 1st Biosimilars for Eylea, Actemra Get NHI Listing in November
November 11, 2025
-
REGULATORY MOF Pushes Stronger Use of CEA for Pricy Meds towards FY2026 Budget
November 11, 2025
-
REGULATORY Growth Strategy Council Seeks Stronger Drug Discovery Infrastructure in Economic Plan
November 11, 2025
-
COMMENTARY Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
November 10, 2025
-
BUSINESS MSD Japan Chief Voices Regret over Delay in Routine HPV Shots for Males
November 10, 2025
-
REGULATORY MHLW Weighs Higher Copay Ratios for LLPs; 1/2 to Full Gap on the Table
November 7, 2025
-
BUSINESS Novo Nordisk Taps Keisuke Kotani as New Japan Chief
November 7, 2025
-
REGULATORY Keytruda Faces 5th Price Cut under Special Re-Pricing; MSD Warns of Ripple Effects
November 6, 2025
-
REGULATORY MOF Floats New Patient Cost Scheme, Eyes Revival of Old Copay System
November 6, 2025
-
REGULATORY Japan Launches Growth Strategy HQ, Sets Drug Discovery as Priority Field
November 5, 2025
-
BUSINESS Fuji, J&J Reach Agreement on Simponi Biosimilar for 2026 Debut
November 5, 2025
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…